Document Detail


Update on the targeted therapy of melanoma.
MedLine Citation:
PMID:  23420410     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Melanoma is the most aggressive of the cutaneous malignancies, causing more than 9,000 deaths in the past year in the United States. Historically, systemic therapies have been largely ineffective, because melanoma is usually resistant to cytotoxic chemotherapy. However, during the past few years, several targeted therapies have proved effective in this challenging disease. These recent advances have been facilitated by an improved understanding of the driving genetic aberrations of melanoma, particularly mutations in the mitogen-activated protein kinase (MAPK) pathway. Vemurafenib, a BRAF inhibitor, demonstrated an overall survival advantage in phase III trials and is an appropriate option for first-line therapy in metastatic BRAF mutant melanoma. Dabrafenib, another BRAF inhibitor, and trametinib, a MEK inhibitor, also have been shown to be effective in phase III trials for BRAF mutant melanoma and may be additional treatment options as monotherapy or in combination pending regulatory approval. Additionally, imatinib is a promising targeted therapy for patients whose tumors harbor a KIT mutation in exons 11 and 13. Although these targeted agents cause objective responses and clinical benefit in patients with metastatic melanoma, resistance invariably develops. New targets and strategies to overcome acquired resistance are urgently needed. Furthermore, no effective targeted therapy has been developed for NRAS mutant tumors or in melanomas with as yet unknown driver mutations. In this review, we discuss current molecular targeted treatment options and promising ongoing research to develop new strategies to treat melanoma.
Authors:
Douglas B Johnson; Jeffrey A Sosman
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current treatment options in oncology     Volume:  14     ISSN:  1534-6277     ISO Abbreviation:  Curr Treat Options Oncol     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-10     Completed Date:  2014-01-23     Revised Date:  2014-04-21    
Medline Journal Info:
Nlm Unique ID:  100900946     Medline TA:  Curr Treat Options Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  280-92     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Drug Delivery Systems / methods
Drug Resistance, Neoplasm
Humans
Melanoma / drug therapy*,  genetics,  metabolism
Molecular Targeted Therapy / methods
Mutation
Skin Neoplasms / drug therapy*,  genetics,  metabolism
Grant Support
ID/Acronym/Agency:
K12 CA090625/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Construction and use of a Trichinella spiralis phage display library to identify the interactions be...
Next Document:  Can clinical tests help monitor human papillomavirus vaccine impact?